Skip to main content
PreveCeutical Medical logo

PreveCeutical Medical — Investor Relations & Filings

Ticker · PREV ISIN · CA74143C1068 LEI · 96760001OJCSH5MXZ450 CSE Professional, scientific and technical activities
Open in API
Filings indexed 438 across all filing types
Latest filing 2023-08-25 Regulatory Filings
Country CA Canada
Listing CSE PREV

About PreveCeutical Medical

https://www.preveceutical.com/

PreveCeutical Medical Inc. is a health sciences company dedicated to the research and development of innovative options for preventive and curative therapies. The company specializes in utilizing organic and nature identical products, combining scientific rigor with natural sources to benefit health-conscious consumers. Its primary focus is on the preventive health sector, collaborating with partners to bring novel solutions to market.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2023-08-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of patent applications in the EU and Australia by PreveCeutical Medical Inc. It discusses intellectual property progress and patent prosecution but does not contain any financial data, regulatory certifications, or detailed financial reports. It is a news release about company activities rather than a formal financial or regulatory filing. The content does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. It is an announcement of a corporate development (patent filing) and not related to capital/financing updates or management changes. Given the nature of the document as a news release about patent filings, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-07-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing and progress of patent applications by PreveCeutical Medical Inc. It discusses patent families, application numbers, jurisdictions, and the company's ongoing prosecution of these patents. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no shareholder meeting materials, no management or board changes, no earnings information, and no legal proceedings. The document is a corporate announcement about intellectual property progress, typical of a general regulatory announcement or news release. It is not a report, nor an announcement of a report publication. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2023-06-28 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. It is a Form 52-109FV2 Certification of Interim Filings for a venture issuer. The text does not contain actual financial data or the interim report itself but is a certification letter confirming the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the interim report (IR) itself. The document length is short (3012 characters), and it is clearly a certification, not the full interim report.
2023-05-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CFO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. It explicitly states it is a certification and does not contain the actual interim financial statements or substantive financial data. According to the CERTIFICATION RULE, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS). The document length is short (3009 characters) and it is a certification letter rather than the interim report itself.
2023-05-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion and Analysis for the three months ended March 31, 2023' and contains detailed management commentary on financial condition, results of operations, business description, forward-looking statements, and corporate structure. It references compliance with National Instrument 51-102, discusses interim financial statements prepared under IAS 34, and explicitly states it should be read with the condensed interim consolidated financial statements for the quarter ended March 31, 2023. The document length is about 15,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the typical characteristics of an Interim / Quarterly Report (IR), which includes actual financial data and management analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-05-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.